Director dealings
Cyprotex PLC ("Cyprotex" or the "Company")
Macclesfield, UK - Cyprotex PLC (LSE: CRX), a Contract Research Organisation (CRO) specialising in the preclinical ADME assessment of drug candidates, was informed on 17 August 2010 that certain directors acquired ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 17 August 2010. Details of the dealings are set out below:
|
Name |
Title |
Price |
Shares acquired |
Total interest following dealing |
% of total issued share capital |
|
Steve Harris |
Chairman |
3.50 |
714,286 |
1,514,286 |
0.68 |
|
Anthony Baxter |
CEO |
3.50 |
228,571 |
1,069,971 |
0.48 |
|
John Dootson |
CFO |
3.50 |
550,000 |
550,000 |
0.25 |
|
Katya Tsaioun |
CSO |
3.50 |
1,828,571 |
24,193,720 |
10.82 |
|
Douglas Bates |
CMO |
3.50 |
5,485,715 |
27,850,862 |
12.45 |
For further information please contact:
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
info@evotec.eu